LUNA Luna Innovations Incorporated gains 25% Mar 29, 2019

Luna Innovations Incorporated develops, manufactures, and markets fiber optic sensing, and test and measurement products worldwide. It operates in two segments, Products and Licensing, and Technology Development. The Products and Licensing segment offers fiber optic sensing, as well as test and measurement products to monitor the integrity of fiber optic network components and sub-assemblies, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; distributed sensing systems comprising optical distributed sensor interrogator sensing solution with multiple sensors whose inputs are integrated through a fiber optic network and software; high speed optical receivers, such as 100G optical receivers and 10G avalanche photodiodes; and terahertz sensing systems. The Technology Development segment provides applied research for customers in areas, such as nanomaterials, coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was founded in 1990 and is headquartered in Roanoke, Virginia.http://www.priceseries.com/trade/LUNA-Luna-Innovations-Incorporated-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2019030120190329.html

SYRS Syros Pharmaceuticals Inc gains 21% Mar 27, 2019

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.http://www.priceseries.com/trade/SYRS-Syros-Pharmaceuticals-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019031220190327.html

SRNE Sorrento Therapeutics, Inc. gains 86% Mar 27, 2019

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.http://www.priceseries.com/trade/SRNE-Sorrento-Therapeutics-Inc-stock-gains-86-percent-a-Trade-Record-by-priceSeries-2019031220190327.html

SNSS Sunesis Pharmaceuticals, Inc. gains 37% Mar 27, 2019

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.http://www.priceseries.com/trade/SNSS-Sunesis-Pharmaceuticals-Inc-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2019031320190327.html

SHIP Seanergy Maritime Holdings Corp gains 17% Mar 27, 2019

Seanergy Maritime Holdings Corp., through its subsidiaries, provides seaborne transportation of dry bulk commodities. The company owns six Capesize and two Supramax vessels. Seanergy Maritime Holdings Corp. was formerly known as Seanergy Maritime Corp. and changed its name to Seanergy Maritime Holdings Corp. in January 2009. The company was founded in 2008 and is based in Athens, Greece. Seanergy Maritime Holdings Corp. operates as a subsidiary of Jelco Delta Holding Corp.http://www.priceseries.com/trade/SHIP-Seanergy-Maritime-Holdings-Corp-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019032620190327.html

NCNA NuCana plc gains 18% Mar 27, 2019

http://www.priceseries.com/trade/NCNA-NuCana-plc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019030820190327.html

LPCN Lipocine Inc. gains 19% Mar 27, 2019

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.http://www.priceseries.com/trade/LPCN-Lipocine-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019022820190327.html

CYTK Cytokinetics, Incorporated gains 24% Mar 27, 2019

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.http://www.priceseries.com/trade/CYTK-Cytokinetics-Incorporated-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019031220190327.html

CHEK Check-Cap Ltd. gains 36% Mar 27, 2019

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.http://www.priceseries.com/trade/CHEK-Check-Cap-Ltd-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2019030720190327.html

CDNA CareDx, Inc. gains 32% Mar 27, 2019

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company's commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.http://www.priceseries.com/trade/CDNA-CareDx-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2019022020190327.html

APTO Aptose Biosciences, Inc. gains 16% Mar 27, 2019

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Kruppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company's APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company's compounds for veterinary medicine. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.http://www.priceseries.com/trade/APTO-Aptose-Biosciences-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019031320190327.html

NTRA Natera, Inc. gains 15% Mar 26, 2019

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company has research collaborations with oncology centers, such as Stanford University, Columbia University, Vanderbilt University, UCSF/I-SPY, and Cancer Research UK. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.http://www.priceseries.com/trade/NTRA-Natera-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019031120190326.html

NBRV Nabriva Therapeutics AG gains 31% Mar 26, 2019

Developing a novel antibiotic for bacterial pneumonia.http://www.priceseries.com/trade/NBRV-Nabriva-Therapeutics-AG-stock-gains-31-percent-a-Trade-Record-by-priceSeries-2019030420190326.html

FLDM Fluidigm Corporation gains 45% Mar 26, 2019

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 system; integrated fluidic circuits (IFCs) consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. The company also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules. It serves academic institutions; clinical research laboratories; biopharmaceutical, biotechnology, and agricultural biotechnology companies; and contract research organizations. Fluidigm Corporation distributes its systems through direct sales force and support organizations located in North America, Europe, and the Asia-Pacific, and through distributors or sales agents in various European, Latin American, Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.http://www.priceseries.com/trade/FLDM-Fluidigm-Corporation-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2019020820190326.html

BASI Bioanalytical Systems, Inc. gains 25% Mar 26, 2019

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, other North America, the Pacific Rim, Europe, and internationally. It operates in two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; preclinical and pathology services; product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; and stability testing to establish and confirm product purity, potency, and shelf life. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.http://www.priceseries.com/trade/BASI-Bioanalytical-Systems-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2019022720190326.html

ARDX Ardelyx, Inc. gains 40% Mar 26, 2019

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.http://www.priceseries.com/trade/ARDX-Ardelyx-Inc-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2019020620190326.html

ZIOP ZIOPHARM Oncology Inc gains 17% Mar 25, 2019

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon's synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.http://www.priceseries.com/trade/ZIOP-ZIOPHARM-Oncology-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019031120190325.html

WMC Western Asset Mortgage Capital Corporation gains 15% Mar 25, 2019

Western Asset Mortgage Capital Corporation operates as a real estate investment trust in the United States. It primarily focuses on investing in, financing, and managing a portfolio of agency and non-agency residential mortgage-backed securities and commercial mortgage-backed securities, residential whole-loans, and other financial assets. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2009 and is based in Pasadena, California.http://www.priceseries.com/trade/WMC-Western-Asset-Mortgage-Capital-Corporation-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019010420190325.html

WBC Wabco Holdings Inc. gains 18% Mar 25, 2019

WABCO Holdings Inc., together with its subsidiaries, provides electronic, mechanical, electro-mechanical, and aerodynamic products for commercial truck, bus, trailer, and passenger car manufacturers worldwide. It engineers, develops, manufactures, and sells control systems, including braking, stability, suspension, transmission automation, and air management systems primarily for commercial vehicles. The company offers pneumatic anti-lock braking systems, electronic braking systems, electronic stability control systems, brake controls, automated manual transmission systems, and air disc brakes; and various conventional mechanical products, such as actuators, air compressors, conventional braking systems, and air control valves for medium and heavy-duty trucks, buses, and trailers, as well as foundation brakes, vehicle electronic stability control and roll stability support systems, and advanced driver assistance systems. It also supplies electronic suspension controls and vacuum pumps to the passenger car and SUV markets, as well as provides remanufacturing services. In addition, the company provides replacement parts, fleet management solutions, diagnostic tools, training, and other services to commercial vehicle aftermarket distributors, service partners, and fleet operators. It also serves truck and bus original equipment manufacturers (OEMs), trailer OEMs, and car manufacturers. WABCO Holdings Inc. was founded in 1869 and is headquartered in Brussels, Belgium.http://www.priceseries.com/trade/WBC-Wabco-Holdings-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019022220190325.html

VRML Vermillion, Inc. gains 51% Mar 25, 2019

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company's lead in vitro diagnostic test is Overa, a blood test to aid physicians in pre-surgical assessment of ovarian tumors for malignancy, using an ialgorithmic approach. It serves clinical reference laboratories, hospital laboratories, and physician offices in the United States. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.http://www.priceseries.com/trade/VRML-Vermillion-Inc-stock-gains-51-percent-a-Trade-Record-by-priceSeries-2019030620190325.html

SE Spectra Energy Corp gains 43% Mar 25, 2019

Spectra Energy Corp owns and operates a portfolio of natural gas-related energy assets in North America. It operates through four segments: Spectra Energy Partners, Distribution, Western Canada Transmission & Processing, and Field Services. The Spectra Energy Partners segment engages in the transmission, storage, and gathering of natural gas, as well as transportation and storage of crude oil and natural gas liquids (NGLs) for customers in various regions of the United States and Canada. Its natural gas pipeline systems consist of approximately 21,000 miles of transmission pipelines; and storage capacity comprises 300 billion cubic feet (Bcf). The Distribution segment offers natural gas storage, transmission, and distribution services for residential, commercial, and industrial customers in Canada. It has approximately 40,000 miles of main and service pipelines; storage capacity of approximately 163 Bcf; and transmission system of approximately 3,000 miles of high-pressure pipeline and mainline compressor stations. The Western Canada Transmission & Processing segment provides natural gas transmission, and gas gathering and processing services; and services to natural gas producers to remove impurities from the raw gas stream, including water, carbon dioxide, hydrogen sulfide, and other substances. It also extracts, fractionates, transports, stores, and markets NGLs for western Canadian producers and NGL customers. It serves local distribution companies, end-use industrial and commercial customers, marketers, and exploration and production companies. The Field Services segment gathers, compresses, treats, processes, transports, stores, and sells natural gas; produces, fractionates, transports, stores, and sells NGLs; recovers and sells condensate; and trades in and markets natural gas and NGLs. It owns or operates approximately 67,000 miles of gathering and transmission pipeline. The company was incorporated in 2006 and is headquartered in Houston, Texas.http://www.priceseries.com/trade/SE-Spectra-Energy-Corp-stock-gains-43-percent-a-Trade-Record-by-priceSeries-2019022620190325.html

PM Philip Morris International Inc gains 23% Mar 25, 2019

Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other tobacco products, and other nicotine-containing products. Its portfolio of brands comprises Marlboro, Merit, Parliament, Virginia S., L&M, Philip Morris, Bond Street, Chesterfield, Lark, Muratti, Next, and Red & White. The company also owns various cigarette brands, such as Dji Sam Soe, Sampoerna, and U Mild in Indonesia; Champion, Fortune, and Jackpot in the Philippines; Apollo-Soyuz and Optima in Russia; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics, and Number 7 in Canada; f6 in Germany; Delicados in Mexico; Assos in Greece; and Petra in the Czech Republic and Slovakia. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, Asia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is based in New York, New York.http://www.priceseries.com/trade/PM-Philip-Morris-International-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019012520190325.html

OZM Och-Ziff Capital Management Group LLC gains 15% Mar 25, 2019

Och-Ziff Capital Management Group LLC is a publicly owned hedge fund sponsor. The firm provides investment advisory services for its clients. It primarily caters to institutional investors which include pension funds, fund-of-funds, foundations and endowments, corporations and other institutions, private banks and family offices. The firm invests in equity and alternative markets across the world. It employs quantitative and qualitative analysis to make its investments. For its multi-strategy portfolios, the firm employs strategies like convertible and derivative arbitrage, corporate credit, long/short equity special situations, buyout investments, merger arbitrage, private investments, and structured credit. It also invests in real estate and traditional real estate assets including multifamily, office, hotel and retail, loans, portfolio acquisitions, loan pools, operating companies, structured debt products, public securities, and non-traditional real estate assets including gaming, distressed land and residential, cell towers, parking, golf, debt and senior housing. For private equity investments, it considers investments in a variety of special situations that seek to realize value through strategic sales or initial public offerings. The firm typically invests in the energy investments. It prefers to invest in United States. It also manages a buyout fund, Och-Ziff Energy Fund. Och-Ziff Capital Management Group LLC was founded in 1994 and is based New York City with additional offices in Houston, Texas, London, United Kingdom, Hong Kong, Tokyo, Japan, Bangalore, India, Singapore, and Beijing, China.http://www.priceseries.com/trade/OZM-Och-Ziff-Capital-Management-Group-LLC-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019030720190325.html

NEOS Neos Therapeutics, Inc. gains 24% Mar 25, 2019

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.http://www.priceseries.com/trade/NEOS-Neos-Therapeutics-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019031320190325.html

NCTY The9 Limited gains 17% Mar 25, 2019

The9 Limited, together with its subsidiaries, operates as an online game developer and operator in the People's Republic of China. The company offers online games, including massively multiplayer online games, mobile games, and TV games. It also provides training services, as well as operates mobile advertising platform. In addition, the company engages in the home entertainment set top box business. The company was formerly known as GameNow.net Limited and changed its name to The9 Limited in February 2004. The9 Limited was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.http://www.priceseries.com/trade/NCTY-The9-Limited-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019031320190325.html

MYOK MyoKardia, Inc. gains 24% Mar 25, 2019

Clinical-stage biotech developing therapies for heritable cardiomyopathies.http://www.priceseries.com/trade/MYOK-MyoKardia-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019021420190325.html

GRVY GRAVITY Co., Ltd. gains 35% Mar 25, 2019

Gravity Co., Ltd. develops and publishes online games in South Korea, Japan, the United States, Canada, Taiwan, Hong Kong, Macau, China, and internationally. It offers online games; mobile games and applications; and other games and game-related products and services, including character-based merchandise and animation. The company's massively multiplayer online role playing games include Ragnarok Online, Ragnarok Online II, Requiem, Dragonica, and R.O.S.E. Online. It also provides console games and a game for Internet protocol television; and licenses the merchandizing rights of character-related products based on its online games. In addition, the company markets dolls, stationery, food, and other character-based merchandise, as well as game manuals, monthly magazines, and other publications. Further, it provides Website development and operation services; and sells goods related to mobile phones, such as ornamental accessories and USB data cables. The company was founded in 2000 and is headquartered in Seoul, South Korea. Gravity Co., Ltd. operates as a subsidiary of GungHo Online Entertainment, Inc.http://www.priceseries.com/trade/GRVY-GRAVITY-Co-Ltd-stock-gains-35-percent-a-Trade-Record-by-priceSeries-2019030120190325.html

GPN Global Payments Inc. gains 15% Mar 25, 2019

Global Payments Inc. provides payment solutions for credit cards, debit cards, electronic payments, and check-related services. It operates in three segments: North America, Europe, and Asia-Pacific. The company's services include authorization services, settlement and funding services, customer support and help-desk functions, chargeback resolution, terminal rental, sales and deployment, payment security services, consolidated billing and statements, on-line reporting, industry compliance, and payment card industry security services. It also provides credit and debit card transaction processing services for various international card brands, including American Express, Discover Card, JCB, MasterCard, UnionPay International, and Visa; and non-traditional payment methods, as well as certain domestic debit networks, such as Interac in Canada. In addition, the company offers integrated commerce, omnichannel, vertically-oriented software, cloud-based point-of-sale, analytics, marketing, payroll, and other solutions; and ecommerce and omnichannel solutions through Realex Payments, a European online payment gateway technology, as well as gaming solutuions to licensed gaming operators. It serves customers in various industries comprising restaurant, hospitality, retail, convenience stores and petroleum, professional services, automotive, and lodging. The company markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, financial institutions, and independent sales organizations in 30 countries of North America, Europe, the Asia-Pacific region, and Brazil. Global Payments Inc. was founded in 1967 and is headquartered in Atlanta, Georgia.http://www.priceseries.com/trade/GPN-Global-Payments-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019020820190325.html

ADVM Adverum Biotechnologies, Inc. gains 16% Mar 25, 2019

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.http://www.priceseries.com/trade/ADVM-Adverum-Biotechnologies-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019031120190325.html

VRA Vera Bradley, Inc. gains 36% Mar 22, 2019

Vera Bradley, Inc., together with its subsidiaries, designs, manufactures, and sells women's handbags, luggage and travel items, fashion and home accessories, and gifts. The company offers totes, crossbodies, satchels, clutches, backpacks, baby, and lunch bags; accessories, inclduing wallets, wristlets, eyeglass cases, jewelry, scarves, and various technology accessories; and travel products, such as rolling luggage, cosmetics, and travel and packing accessories, as well as travel bags comprising duffel and weekend bags. It also provides home products consisting of mugs and tumblers, as well as textiles products, such as throw blankets, beach towels, comforters, and wellness and beauty products; offers apparel/footwear, stationery, merchandising, and gift card products; and licenses its products. The company sells its products through two segments, Direct and Indirect. The Direct segment sells Vera Bradley branded products through the company's factory outlet stores in the United States, verabradley.com, and direct-to-consumer eBay sales, as well as through its annual outlet sale in Fort Wayne, Indiana. The Indirect segment offers Vera Bradley branded products to approximately 2,600 specialty retail locations located in the United States, as well as department stores, national accounts, third party e-commerce sites and inventory liquidators, and its wholesale customer in Japan. As of January 28, 2017, the company operated 113 full-line stores and 46 factory outlet stores. Vera Bradley, Inc. was founded in 1982 and is headquartered in Roanoke, Indiana.http://www.priceseries.com/trade/VRA-Vera-Bradley-Inc-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2019021520190322.html

TNDM Tandem Diabetes Care, Inc. gains 58% Mar 22, 2019

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system. In addition, the company offers Tandem Device Updater, a PC and Mac-compatible Web-based system that allows users to update their pump's software; t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:90 and t:30 infusion sets for use with its insulin pump products; and various pump accessories. Its products in development include t:slim X2 with G5 integration; automated insulin delivery systems; t:slim X2 with PLGS; t:slim X2 with TypeZero; and t:sport insulin delivery system. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.http://www.priceseries.com/trade/TNDM-Tandem-Diabetes-Care-Inc-stock-gains-58-percent-a-Trade-Record-by-priceSeries-2019021120190322.html

TGTX TG Therapeutics, Inc. gains 63% Mar 22, 2019

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.http://www.priceseries.com/trade/TGTX-TG-Therapeutics-Inc-stock-gains-63-percent-a-Trade-Record-by-priceSeries-2019020820190322.html

TENX Tenax Therapeutics, Inc. gains 15% Mar 22, 2019

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company offers Wundecyte, a wound-healing gel. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.http://www.priceseries.com/trade/TENX-Tenax-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019031420190322.html

RUBI The Rubicon Project, Inc. gains 73% Mar 22, 2019

The Rubicon Project, Inc., a technology company, engages in automating the purchasing and selling of advertising. The company offers advertising automation platform that creates and powers a marketplace for buyers and sellers to readily buy and sell advertising at scale. Its advertising automation platform features applications and services for digital advertising sellers, including Websites, mobile applications, and other digital media properties to sell their advertising inventory; applications and services for buyers comprising advertisers, agencies, agency trading desks, demand side platforms, and ad networks to buy advertising inventory; and a marketplace over which such transactions are executed. The company was founded in 2007 and is headquartered in Los Angeles, California.http://www.priceseries.com/trade/RUBI-The-Rubicon-Project-Inc-stock-gains-73-percent-a-Trade-Record-by-priceSeries-2019010420190322.html

RTIX RTI Surgical, Inc. gains 21% Mar 22, 2019

RTI Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes orthopedic and other surgical implants for use in various surgical procedures worldwide. The company provides natural tissue implants, as well as metal and synthetic implants for the treatment of spinal and other orthopedic disorders. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendons, ligaments, fascia lata, pericardium, sclera, cornea, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company's implants are used in the fields of spine, sports medicine, orthobiologics, bone graft substitutes and general orthopedic, trauma, dental, and surgical specialties. RTI Surgical, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.http://www.priceseries.com/trade/RTIX-RTI-Surgical-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019022720190322.html

QURE uniQure N.V. gains 72% Mar 22, 2019

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.http://www.priceseries.com/trade/QURE-uniQure-NV-stock-gains-72-percent-a-Trade-Record-by-priceSeries-2019021520190322.html

OLED Universal Display Corporation gains 57% Mar 22, 2019

Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel displays and solid-state lighting applications. It owns, exclusively licenses, or has the sole right to sublicense approximately 4,200 patents issued and pending worldwide. The company licenses and supplies its proprietary UniversalPHOLED materials to display manufacturers and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates; UniversalP2OLED, which are printable phosphorescent OLEDs; OVJP, an organic vapor jet printing technology; OVPD, an organic vapor phase deposition for manufacturing a small molecule OLED; and TOLED, which are transparent OLEDs for the fabrication of OLEDs that have transparent cathodes. In addition, the company provides technology development and support services, including government contract work and support provided to third parties for the commercialization of their OLED products. It has strategic relationships with Samsung Display Co., Ltd.; LG Display Co., Ltd.; AU Optronics Corporation; BOE Technology Group Co., Ltd.; Innolux Corporation; Kaneka Corporation; Konica Minolta Holdings Inc.; Lumiotec, Inc.; LG Chem, Ltd.; NEC Lighting, Ltd.; Osram GmbH; Pioneer Corporation; Sony; Sumitomo Chemical Co., Ltd.; and Tianma Micro-electronics Co., Ltd. The company was founded in 1985 and is headquartered in Ewing, New Jersey.http://www.priceseries.com/trade/OLED-Universal-Display-Corporation-stock-gains-57-percent-a-Trade-Record-by-priceSeries-2019012420190322.html

NXST Nexstar Broadcasting Group, Inc. gains 23% Mar 22, 2019

Nexstar Media Group, Inc. operates as a television broadcasting and digital media company in the United States. It focuses on the acquisition, development, and operation of television stations and interactive community Websites in medium-sized markets. The company offers free over-the-air programming to television viewing audiences. It also provides sales, programming, and other services through various local service agreements to 30 power television stations owned and/or operated by independent third parties. As of December 31, 2016, the company owned, operated, programmed, or provided sales and other services to 104 television stations in 62 markets in the states of Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa, Louisiana, Maryland, Michigan, Missouri, Montana, Nevada, New York, North Dakota, Pennsylvania, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, and Wisconsin. The company's stations reach approximately 20.8 million viewers. The company was formerly known as Nexstar Broadcasting Group, Inc. and changed its name to Nexstar Media Group, Inc. in January 2017. Nexstar Media Group, Inc. was founded in 1996 and is headquartered in Irving, Texas.http://www.priceseries.com/trade/NXST-Nexstar-Broadcasting-Group-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019021120190322.html

NVTA Invitae Corporation gains 16% Mar 22, 2019

Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare in the United States, Canada, Israel, and internationally. The company processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. It provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. The company also offers solutions that enable sharing of genetic information consisting of Invitae Family History Tool, an online portal and mobile application that communicates sensitive patient data. In addition, it provides gene sequencing and deletion/duplication analysis; and free re-requisition of additional data within the same indication when ordered, as well as invests in informatics solutions and infrastructure that enable sharing of genetic information to enhance healthcare and clinical outcomes. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.http://www.priceseries.com/trade/NVTA-Invitae-Corporation-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019030720190322.html

NTLA Intellia Therapeutics Inc gains 15% Mar 22, 2019

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.http://www.priceseries.com/trade/NTLA-Intellia-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019022520190322.html

LMAT LeMaitre Vascular, Inc. gains 26% Mar 22, 2019

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature. In addition, the company provides radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin; and remote endarterectomy devices to remove plaque from arteries in the leg. Further, it offers valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; vascular grafts to bypass or replace diseased arteries; vascular patches, which are used for precision endarterectomy vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and laparoscopic cholecystectomy devices to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through direct and indirect sales force. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.http://www.priceseries.com/trade/LMAT-LeMaitre-Vascular-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2019021120190322.html

IMMU Immunomedics, Inc. gains 18% Mar 22, 2019

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.http://www.priceseries.com/trade/IMMU-Immunomedics-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019022220190322.html

FSCT ForeScout Technologies, Inc. gains 58% Mar 22, 2019

http://www.priceseries.com/trade/FSCT-ForeScout-Technologies-Inc-stock-gains-58-percent-a-Trade-Record-by-priceSeries-2019012320190322.html

ECL Ecolab Inc. gains 18% Mar 22, 2019

Ecolab Inc. provides water, hygiene, and energy technologies and services for customers worldwide. The company operates in three segments: Global Industrial, Global Institutional, and Global Energy. The Global Industrial segment provides water treatment and process applications, and cleaning and sanitizing solutions primarily to large industrial customers within the manufacturing, food and beverage processing, chemical, mining and primary metals, power generation, pulp and paper, and commercial laundry industries. The Global Institutional segment offers specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, healthcare, government and education, and retail industries. The Global Energy segment provides the process chemicals and water treatment needs of the petroleum and petrochemical industries in upstream and downstream applications. The company also offers pest elimination services to detect, eliminate, and prevent pests, such as rodents and insects, in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations, and other institutional and commercial customers; and equipment repair, maintenance, and preventive maintenance services for the commercial food service industry. Ecolab Inc. sells its products through field sales personnel, corporate account personnel, distributors, and dealers. Ecolab Inc. was founded in 1923 and is headquartered in St. Paul, Minnesota.http://www.priceseries.com/trade/ECL-Ecolab-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019010420190322.html

DBD Diebold, Incorporated gains 153% Mar 22, 2019

Diebold Nixdorf, Incorporated provides connected commerce services, software, and technology for financial, commercial, and industrial customers. The company operates in four segments: North America; Asia Pacific; Europe, Middle East and Africa; and Latin America. It offers financial self-service solutions and technologies, including automated teller machine (ATM) outsourcing, ATM security, deposit automation, recycling and payment terminals, and software. The company also provides financial self-service support and maintenance services comprising installation and ongoing maintenance of products, availability management, branch automation, and distribution channel consulting; outsourced and managed services, such as remote monitoring, troubleshooting, transaction processing, currency management, maintenance, and online communication services; and strategic analysis and planning for new systems, systems integration, architectural engineering, consulting, and project management services, as well as multi-vendor services. In addition, it offers electronic security services and products; security monitoring solutions comprising remote monitoring and diagnostics, fire detection, intrusion protection, managed access control, energy management, remote video management and storage, logical security, and Web-based solutions; and physical security and facility products. Further, the company provides development, training, support, and maintenance of elections and lottery equipment, networking, tabulation, and diagnostic software; and IT solutions and services to retail banks and the retail industry. The company was formerly known as Diebold, Incorporated and changed its name to Diebold Nixdorf, Incorporated in December 2016. Diebold Nixdorf, Incorporated was founded in 1859 and is headquartered in North Canton, Ohio.http://www.priceseries.com/trade/DBD-Diebold-Incorporated-stock-gains-153-percent-a-Trade-Record-by-priceSeries-2019013120190322.html

CTRP Ctrip.com International, Ltd. gains 18% Mar 22, 2019

Ctrip.com International, Ltd., together with its subsidiaries, provides travel service for accommodation reservation, transportation ticketing, packaged tours, and corporate travel management in the People's Republic of China. The company operates as an agent for hotel-related transactions; sells air tickets; and other related services, including sale of aviation and train insurance, air-ticket delivery services, online check-in, and other value-added services, such as online seat selection and flight dynamics. It also provides independent leisure travelers bundled packaged-tour products comprising group tours, semi-group tours, and customized tours and packaged tours with various transportation arrangements, such as flights, cruises, and buses, as well as car rental services. In addition, the company offers integrated transportation and accommodation services; various value-added services, such as transportation at destinations and tickets, insurance, visa services, and tour guides; and supplier management and customer relationship management services. Further, it provides travel data collection and analysis, industry benchmark, cost saving analysis, and travel management solutions; and Corporate Travel Management System, an online platform that integrates information maintenance, online booking and authorization, online enquiry, and travel report system. Additionally, the company offers online advertising services; and sells Property Management System, as well as provides related maintenance services. Ctrip.com International, Ltd. was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.http://www.priceseries.com/trade/CTRP-Ctripcom-International-Ltd-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019022820190322.html

CRAI CRA International,Inc. gains 18% Mar 22, 2019

CRA International, Inc., a consulting company, provides economic, financial, and management consulting services worldwide. The company advises clients on economic and financial matters pertaining to litigation and regulatory proceedings; and guides corporations through critical business strategy and performance-related issues. It provides consulting services, including research and analysis, expert testimony, and support in litigation and regulatory proceedings in the areas of finance, accounting, economics, insurance, and forensic accounting and investigations to corporate clients and attorneys. The company also offers services related to class certification, damages analysis, expert reports and testimony, regulatory analysis, strategy development, valuation of tangible and intangible assets, risk management, and transaction support to law firms, businesses, and government agencies. In addition, it provides management consulting services, such as strategy development, performance improvement, corporate strategy and portfolio analysis, estimation of market demand, new product pricing strategies, valuation of intellectual property and other assets, assessment of competitors' actions, and analysis of new sources of supply. The company serves various industries, including agriculture; banking and capital markets; chemicals; communications and media; consumer products; energy; entertainment; financial services; health care; insurance; life sciences; manufacturing; metals, mining, and materials; oil and gas; real estate; retail; sports; telecommunications; transportation; and technology. Further, it develops and markets neural network software tools, as well as provides complementary application consulting services primarily for electric utilities. CRA International, Inc. was founded in 1965 and is headquartered in Boston, Massachusetts.http://www.priceseries.com/trade/CRAI-CRA-InternationalInc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019021420190322.html

BOLD Audentes Therapeutics Inc gains 50% Mar 22, 2019

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.http://www.priceseries.com/trade/BOLD-Audentes-Therapeutics-Inc-stock-gains-50-percent-a-Trade-Record-by-priceSeries-2019021520190322.html

BIO Bio-Rad Laboratories, Inc. gains 21% Mar 22, 2019

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. It operates in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.http://www.priceseries.com/trade/BIO-Bio-Rad-Laboratories-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019021120190322.html